Abstract：Objective To determine the levels of serum calcium-binding protein (S100) A6 and S100A12 in patients with Parkinson's disease (PD) and osteoporosis and analyze their clinical significance. Methods A total of 134 PD patients admitted to Shandong Provincial Corps Hospital of Chinese People's Armed Police Force from April 2021 to March 2024 were selected and divided into an osteoporosis group (n=53) and a non-osteoporosis group (n=81) according to the occurrence of osteoporosis. Pearson correlation analysis was used to analyze the relationship between serum S100A6, S100A12 and bone metabolism markers. Multivariate Logistic regression analysis was used to analyze the risk factors affecting osteoporosis in PD patients, and receiver operating characteristic (ROC) curve was drawn to analyze the predictive value of the two indicators for osteoporosis in PD patients. Results Among 134 PD patients, 53 cases developed osteoporosis(39.55%). Compared with non-osteoporosis group, serum levels of S100A6 and S100A12 in osteoporosis group increased (P<0.05). The type I procollagen amino-terminal propeptide (PINP) and 25-hydroxyvitamin D [25(OH)D] levels in osteoporosis group were lower than those in non-osteoporosis group, while the type I collagen C-terminal peptide (S-CTX) and β-collagen specific sequence (β-CTX) levels were higher than those in non-osteoporosis group (P<0.05). Pearson correlation analysis showed that serum S100A6 and S100A12 were negatively correlated with PINP and 25 (OH) D (P<0.05), but positively correlated with S-CTX and β-CTX (P<0.05). Multivariate Logistic regression analysis showed that old age, female, advanced disease and elevated serum S100A6 and S100A12 were independent risk factors for osteoporosis in PD patients (P<0.05). ROC curve showed that serum S100A6 and S100A12 alone predicted the AUC of osteoporosis in PD patients were 0.665 and 0.746 respectively, the combined predicted AUC was 0.913 (0.872-0.945), and the combined prediction efficiency was higher than that of single index (P<0.05). Conclusions Serum S100A6 and S100A12 are abnormally elevated in PD patients with osteoporosis and they are correlated with bone metabolism, which is helpful for screening PD patients with osteoporosis.
刘洋, 王珂, 程刚, 刘甲. 帕金森病伴骨质疏松症患者血清S100A6、S100A12水平及其临床意义[J]. 武警医学, 2025, 36(4): 319-324.
LIU Yang, WANG Ke, CHENG Gang, LIU Jia. Serum levels of S100A6 and S100A12 in patients with Parkinson's disease and osteoporosis and their clinical significance. Med. J. Chin. Peop. Armed Poli. Forc., 2025, 36(4): 319-324.
Morris H R, Spillantini M G, Sue C M, et al. The pathogenesis of Parkinson's disease[J]. Lancet, 2024, 403(10423): 293-304.
[2]
Cattaneo C, Jost W H. Pain in Parkinson's disease: pathophysiology, classification and treatment[J]. J Integr Neurosci, 2023, 22(5): 132.
[3]
Feng S H, Huang Y P, Yeh K C, et al. Osteoporosis and the risk of Parkinson's disease: a nationwide, propensity score-matched, longitudinal follow-up study[J]. J Clin Endocrinol Metab, 2021, 106(2): e763-e771.
[4]
Kim T L, Byun S J, Seong M Y, et al. Fracture risk and impact of osteoporosis in patients with Parkinson's disease: a nationwide database study[J]. J Bone Miner Metab, 2022, 40(4): 602-612.
Lee S H, Ihn H J, Park E K, et al. S100 Calcium-binding protein P secreted from megakaryocytes promotes osteoclast maturation[J]. Int J Mol Sci, 2021, 22(11): 6129.
[7]
Wang T, Zhu G, Wang B, et al. Activation of hypoxia inducible factor-1 Alpha-mediated DNA methylation enzymes (DNMT3a and TET2) under hypoxic conditions regulates S100A6 transcription to promote lung cancer cell growth and metastasis[J]. Antioxid Redox Signal, 2024, 41(1-3): 138-151.
[8]
Yang F, Ma J, Zhu D, et al. The role of S100A6 in human diseases: molecular mechanisms and therapeutic potential[J]. Biomolecules, 2023, 13(7): 1139.
[9]
Chen L, Wang Y, Huang J, et al. Identification of immune-related hub genes in Parkinson's disease[J]. Front Genet, 2022, 13(7): 914645.
Goetz C G, Poewe W, Rascol O, et al. Movement disorder society task force report on the hoehn and yahr staging scale: status and recommendations[J]. Mov Disord, 2004, 19(9): 1020-1028.
Wáng Y X J, Griffith J F, Blake G M, et al. Revision of the 1994 World Health Organization T-score definition of osteoporosis for use in older East Asian women and men to reconcile it with their lifetime risk of fragility fracture[J]. Skeletal Radiol, 2024, 53(4): 609-625.
[14]
Goetz C G, Liu Y, Stebbins G T, et al. Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the unified Parkinson's disease rating scale[J]. Mov Disord, 2016, 31(12): 1865-1873.
[15]
Folstein M F, Folstein S E, McHugh P R. “Mini-mental state”. a practical method for grading the cognitive state of patients for the clinician[J]. J Psychiatr Res, 1975, 12(3): 189-198.
[16]
Nasreddine Z S, Phillips N A, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment[J]. J Am Geriatr Soc, 2005, 53(4): 695-699.
Cui Y, Lv B, Li Z, et al. Bone-targeted biomimetic nanogels re-establish osteoblast/osteoclast balance to treat postmenopausal osteoporosis[J]. Small, 2024, 20(6): e2303494.
[20]
Filipek A, Lesniak W. S100A6 and its brain ligands in neurodegenerative disorders[J]. Int J Mol Sci, 2020, 21(11): 3979.
[21]
Lachén-Montes M, González-Morales A, Iloro I, et al. Unveiling the olfactory proteostatic disarrangement in Parkinson's disease by proteome-wide profiling[J]. Neurobiol, 2019,73: 123-134.
Fan Y, Li Q, Liu Y, et al. Sex- and age-specific prevalence of osteopenia and osteoporosis: sampling survey[J]. JMIR Public Health Surveill, 2024, 10(2): e48947.
2025, Vol. 36 
